Inclusion Criteria:

          -  >2 months - 30 years

          -  Patient must have a malignant or non-malignant disease that can benefit from
             alternative stem cell transplantation according to standard practice guidelines for
             including patients for transplant as outlined in UCSF Pediatric Bone Marrow Transplant
             (BMT) Standard Operating Procedure (SOP) #206.04. Examples include acute and chronic
             leukemias, myelodysplastic syndrome, lymphoma, severe acquired and congenital
             cytopenias, white and red blood cell abnormalities, inborn errors of metabolism and
             immunodeficiencies. Patient with Fanconi's Anemia will be eligible regardless of match
             with donor.

          -  Patients with acute leukemia (AML excepted) or lymphoma must be in remission at the
             time of transplant.

          -  Patients must lack a healthy human leukocyte antigen (HLA)-identical related donor.

          -  Recipient or authorized guardian must sign informed consent for this study.

          -  If recipient is female and of child-bearing age, negative pregnancy test.

          -  Patient must have a healthy, willing mismatched related or an unrelated donor who is:

               -  Able to receive Granulocyte colony-stimulating factor (G-CSF) +/- Plerixafor and
                  undergo apheresis either through placement of catheters in antecubital veins or a
                  temporary central venous catheter,

               -  For Related donor: sibling, half-sibling, parent, cousin, aunt, uncle or
                  grandparent will all be considered eligible.

               -  For Related donor: HLA antigen genotypic match ≥ 4/8 and ≤ 7/8 (haplocompatible).

               -  For unrelated donor: 6/8 or 7/8 HLA antigen match (if two mismatches, they must
                  be at different loci).

               -  Complete medical history, physical and screening for infectious diseases that are
                  acceptable for donation.

               -  If donor is female and of child-bearing age, negative pregnancy test.

               -  Absence of anti-HLA antibodies in recipient directed against donor antigens.

               -  Donor must be willing to sign informed consent for this study. If donor is < 18
                  years of age, donor must be willing to give assent and parents willing to sign
                  informed consent.

          -  Be suitable for an autologous gene-modified transplant:

               -  Using either bone marrow or cytokine-mobilized peripheral blood stem cells
                  (PBSC).

               -  Patient or authorized guardian must sign informed consent for this study.

          -  For unrelated donors: Per New Algorithm, Jan. 14, 2016, effective immediately,
             National Marrow Donor Program (NMDP) "Be The Match" is adopting a revised algorithm
             for determining if a donor is a research subject on their recipient's research
             protocol: The NMDP will inform the donor of the activities and the use of donor's
             apheresis product to be used in this study and obtain written consent from the donor.
             Transplant centers are sent documentation of the donor consent to participate in the
             research support activities. (The revised algorithm can be found on the "Be the Match
             Clinical Network")

          -  Criteria to consider when choosing among related haplo donors:

               -  CMV positive donor is preferred over other factors. CMV negative donor can be
                  used only if recipient is CMV negative.

               -  HLA disparity i.e. 2 Ag mismatch preferred over 3 Ag mismatch; Drβ1 match
                  preferred over class I match; HLA-C matched preferred over A and B match.

               -  killer immunoglobulin-like receptor (KIR) mismatch in GVH direction is preferred
                  for patients with malignant disorders

               -  ABO compatibility

          -  Age ≥ 2 months

        Exclusion Criteria:

          -  Patient with an anticipated life expectancy of < 1 month

          -  Active infectious hepatitis or cytomegalovirus (CMV) disease (organ involvement)

          -  Human immunodeficiency virus (HIV) or Human T-lymphotropic virus (HTLV-I/II) infection

          -  Cardiac ejection fraction < 45%; can be lower if patient is not in clinical cardiac
             failure and a reduced intensity conditioning regimen is used.

          -  Creatinine clearance <60 ml/min/1.72 m2; can be lower if a reduced intensity
             conditioning regimen is used.

          -  Pulmonary diffusion capacity (corrected for hemoglobin), forced expiratory volume in
             one second (FEV1), or forced vital capacity (FVC) <60% of predicted or oxygen
             saturation (O2 sat) > 94% on room air if unable to perform pulmonary function tests
             (PFTs); can be lower if a reduced intensity conditioning regimen is used.

          -  Serum alanine aminotransferase (ALT) > 5 x upper limit of normal (can be up to 10x
             upper limit of normal if a reduced intensity conditioning regimen is used) or
             bilirubin > 2.

          -  Performance score (Lansky/Karnofsky) < 50

          -  Any condition that compromises compliance with the procedures of this protocol, as
             judged by the principal investigator.